Photo: Closeup of microscope


Fingolimod (also known as Gilenya) is a tablet developed by Novartis for relapsing MS. A phase 3 clinical trial testing fingolimod as a treatment for primary progressive MS was reported to be unsuccessful in 2016.

Current phase of trial: phase 3 unsuccessful

Type of MS: primary progressive MS (available for relapsing MS)

Find out more about fingolimod